title: Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.
abstract: Mother-to-child transmission (MTCT) of HIV-1 remains a global health problem. The World Health Organization (WHO) recommendations advise the administration of a once-daily, oral, prophylactic regimen of the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) from birth until 4 to 6 weeks of age for infants born to HIV-infected mothers in regions without access to safe and nutritionally adequate alternatives to breast milk. A critical factor driving the successful implementation of the WHO guidelines involves sustaining high adherence to the frequent dosing. With these challenges in mind, we have developed the first injectable, sustained-release NVP formulations with the goal of providing, for 6 weeks or longer, preventative plasma drug levels from a single subcutaneous administration at birth. The long-acting NVP consists of large (>50 μm), monodisperse NVP particles coated with biocompatible polymers that control the drug release kinetics. Two lead formulations exhibiting burst-free, sustained-release kinetics for up to 75 days in vitro were developed. Subsequent in vivo studies in rats demonstrated no toxicity related to the formulations. Rat plasma NVP concentrations were above the analytical assay's limit of quantification for up to 28 days. Pharmacokinetic analysis of the rat plasma NVP concentration-time data allowed absorption rate constants to be calculated. These data then were used to simulate infant NVP exposure from a single injected dose (<200 mg) of our long-acting formulations, demonstrating preliminary feasibility of the technology to maintain safe, preventative NVP plasma levels (0.2 to 3.0 μg ml(-1)) for 6 weeks or longer.
authors.affiliation: Auritec Pharmaceuticals, Inc., Pasadena, California, USA.
authors.forename: John M
authors.initials: JM
authors.lastname: Cortez
authors.affiliation: Auritec Pharmaceuticals, Inc., Pasadena, California, USA.
authors.forename: Rafaela
authors.initials: R
authors.lastname: Quintero
authors.affiliation: Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Moss
authors.affiliation: Pharsight Consulting Services, Montreal, Quebec, Canada.
authors.forename: Martin
authors.initials: M
authors.lastname: Beliveau
authors.affiliation: Auritec Pharmaceuticals, Inc., Pasadena, California, USA Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Smith
authors.affiliation: Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA m.baum@oak-crest.org.
authors.forename: Marc M
authors.initials: MM
authors.lastname: Baum
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000517:prevention & control*; D000818:Animals; D001942:Breast Feeding; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019829:Nevirapine / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D003692:Delayed-Action Preparations; D019829:Nevirapine